



# Sulfhydryl variable-5 extended spectrum $\beta$ -lactamase in nosocomial enteric bacteria causing sepsis in mexican children

Angélica Flores-Pérez<sup>1</sup>  
Catalina Gayosso-Vázquez<sup>2</sup>  
María Dolores Alcántar-Curiel<sup>2</sup>  
Patricia Arzate-Barbosa<sup>3</sup>  
Celia Alpuche-Aranda<sup>4</sup>  
José Luis Arredondo-García<sup>1</sup>

<sup>1</sup> Laboratorio de Investigación Clínica, Instituto Nacional de Pediatría. D.F, México.

<sup>2</sup> Laboratorio de Infectología, Microbiología e Inmunología, Facultad de Medicina, Universidad Nacional Autónoma de México, México, D.F.

<sup>3</sup> Laboratorio de Bacteriología, Instituto Nacional de Pediatría, México, D.F.

<sup>4</sup> Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Salud Pública Cuernavaca, Morelos, México.

## ABSTRACT

**Introduction:** Enteric bacteria causing nosocomial infections are often resistant to third-generation cephalosporins due to the production of extended-spectrum  $\beta$ -lactamases (ESBLs).

**Objective:** To describe and characterize the ESBLs pattern present in *Klebsiella pneumoniae* and *Serratia marcescens* strains, isolated as causative of nosocomial sepsis in pediatric patients at Instituto Nacional de Pediatría (National Institute of Pediatrics).

**Material and methods:** We analyzed 94 strains of *K. pneumoniae* and 7 of *S. marcescens* isolated from clinical specimens from 2002-2005, causative of sepsis in a children's hospital. We evaluated antibiotic susceptibility and detection of ESBL phenotypes by disk diffusion methods; ceftazidime-resistant isolates were further characterized by pulsed field gel electrophoresis (PFGE); and ESBLs were phenotypically and genotypically characterized by isoelectric focusing, polymerase chain reaction (PCR) and sequencing. We also assed for presence of conjugative plasmids bearing the ESBL gene.

**Results:** 51/94 (54%) of *K. pneumoniae* isolates, and 5/7 (71%) of *S. marcescens* isolates were resistant to ceftazidime; all carried a *bla*<sub>SHV-5</sub> gene. All *K. pneumoniae* isolates had a distinct PFGE profile, yet all carried a ~48-Kb plasmid, that was conjugatively transferable to an *Escherichia coli* receptor, which expressed the resistance phenotype. On the other hand, all *S. marcescens* isolates had a similar PFGE profile, were unable to transfer the ceftazidime-resistance phenotype, and were isolated from the same ward in a short time-span suggesting an outbreak.

**Conclusions:** The overall prevalence of ESBL-producing enteric bacteria in this hospital is high but similar to other Latin American reports. The sulfhydryl variable-5 (SHV-5) ESBL gene appears to reside in a highly mobile plasmid, capable of spreading among different *K. pneumoniae* clones and perhaps even to *S. marcescens*.

**Keywords:** SHV-5, extended-spectrum beta-lactamase, *Klebsiella pneumoniae*, *Serratia marcescens*.

Recibido: 15 de mayo del 2015

Aceptado: 11 de septiembre del 2015

**Correspondencia:** Dr. José Luis Arredondo-García  
Laboratorio de Investigación Clínica  
Instituto Nacional de Pediatría  
Insurgentes Sur 3700-C  
CP 04530, México D.F.  
joselag@unam.mx

## Este artículo debe citarse como

Flores-Pérez A, Gayosso-Vázquez C, Alcántar-Curiel MD, Arzate-Barbosa P, Alpuche-Aranda C, Arredondo-García JL. Sulfhydryl variable-5 extended spectrum  $\beta$ -lactamase in nosocomial enteric bacteria causing sepsis in mexican children. Acta Pediatr Mex 2015;36:383-388.

## INTRODUCTION

Both *Klebsiella pneumoniae* and *Serratia marcescens* are opportunistic pathogens causing nosocomial infections (NI), such as pneumonia, meningitis, bacteremia, endocarditis, conjunctivitis, and urinary tract and wound infections.<sup>1,2</sup> Infections caused by *S. marcescens* or *K. pneumoniae* have been linked with various hospital sources, such as medical devices, milk, topical and intravenous solutions, liquid soap and air-conditioning systems.<sup>1-3</sup> Both bacterial species often cause nosocomial outbreaks and are also commonly resistant to cephalosporins (through the production of extended-spectrum  $\beta$ -lactamases, ESBLs) and aminoglycosides<sup>2-4</sup> ESBLs have a serine moiety in their active sites, and can hydrolyze the  $\beta$ -lactam ring of third-generation cephalosporins and monobactams; genes encoding ESBLs can be chromosomal or plasmid-borne.<sup>5-7</sup> Since their first characterization, in the 1980's and 1990's in Germany and France, ESBLs have spread worldwide.<sup>8</sup> Changes in the amino acid sequence produce novel enzymes with modified, increased spectrum.<sup>5,8</sup> The list of ESBL varieties and families is constantly growing; so far, there are 217 enzymes belonging to the TEM family, 184 to the sulfhydryl variable (SHV) family and 18 to the OXA family, for instance ([www.lahey.org/Studies](http://www.lahey.org/Studies)).

In Mexico, previous reports have identified SHV-2, -5 and -12, TLA-1 and CTX-M-15 in *K. pneumoniae*,<sup>9-17</sup> and SHV-2, -5 and -12 in *S. marcescens*.<sup>10,15,18</sup>

## OBJECTIVE

The objective of this study was to describe and characterize the ESBL and associate their presence with the mechanism of the resistance to third generation cephalosporins, which are one of the families of antibiotics used in the treatment

of infections by *K. pneumoniae* and *S. marcescens* at Instituto Nacional de Pediatría (National Institute of Pediatrics).

## MATERIAL AND METHODS

**Bacterial isolates.** One-hundred and one isolates from blood cultures of different hospitalized patients were analyzed from January 2002 to December 2005; 94 were *K. pneumoniae* (26 from the surgery ward, 17 from the oncology ward, 14 from the intensive care unit, and 37 from seven other wards) and 7 were *S. marcescens* (all from the oncology ward, 2-14 January 2003). Biochemical identification was performed using the API 20E (bioMérieux) system.

**Antibiotic susceptibility assays.** Susceptibility towards ampicillin (AMP), amikacin (AMK), aztreonam (ATM), ceftazidime (CAZ), ciprofloxacin (CIP), cefotaxime (CTX), cefuroxime (CXM), cefepime (FEP), ceftazidime (FOX), gatifloxacin (GAT), gentamicin (GEN), imipenem (IPM), levofloxacin (LVX), tobramycin (TOB), ofloxacin (OFX), streptomycin (STR), trimethoprim-sulfamethoxazole (SXT), tetracycline (TET), ticarcillin (TIM), and piperacillin-tazobactam (TZP) was assessed by the disk diffusion method, following Clinical Laboratory Standard Institute (CLSI) guidelines<sup>19</sup> and using Becton-Dickinson disks. Minimum inhibitory concentration (MIC) was inferred from the diameter of inhibitory halos using the BIOMIC System (Giles Scientific).

**ESBLs phenotypic detection.** The double-disk method,<sup>19</sup> using CTX and CAZ disks, alone and in combination with a clavulanic acid disk was used to detect ESBLs. *Escherichia coli* ATCC25922 was used as negative control and as positive control *K. pneumoniae* ATCC700603, following the CLSI standards. The production of inducible AmpC  $\beta$ -lactamases was assessed by a double-disk method<sup>20</sup> using CAZ and FOX disks.



*Genotyping by pulsed field gel electrophoresis (PFGE).* Chromosomal DNA, digested with *Xba*I and *Spe*I (Gibco), was resolved in a 1% agarose gel using a CHEF Mapper XA System (Bio-Rad) running for 17 h at 6V/cm, with pulses of 2-17 s, as previously reported.<sup>21</sup> Gels were stained with ethidium bromide and visualized on a Gel-Doc system (Bio-Rad). Images were interpreted according to<sup>22</sup> *Isoelectric focusing (IEF) of  $\beta$ -lactamases.* The isoelectric point (pI) of identified ESBLs was assessed as described by Mathew et al.<sup>23</sup> Briefly, extracts obtained by sonication<sup>24</sup> were run in ampholine-containing gels (Pharmacia Phast) with a 3-9 pH gradient, and run in a PhastSystem system (Pharmacia).  $\beta$ -lactamase activity in the IEF gel was determined by using nitrocefin (500 mg/mL) in combination with CAZ (8 mg/mL), covering the gel agar containing *E. coli* J53-2 (CAZ-sensitive) 10<sup>6</sup> CFU/mL and incubating at 37°C for 16-24 h.

*Plasmid extraction.* Plasmids were extracted by alkaline lysis<sup>25</sup> and visualized by electrophoresis on 0.7% agarose gels stained with ethidium bromide and checked under UV light.

*Conjugal transfer.* Using CAZ-resistant *K. pneumoniae* and *S. marcescens* clinical isolates as donors, and *E. coli* J53-2 (rifampicin resistant) as recipient, conjugation experiments were performed according to Miller.<sup>26</sup> Transconjugant bacteria were selected on LB agar supplemented with rifampicin (200  $\mu$ g/mL) and CAZ (1  $\mu$ g/mL), identified with API-20E, and CAZ-resistance phenotype confirmed by the double-disk method, as described above.

*Detection of bla<sub>SHV</sub> by PCR.* Plasmid DNA extracted as described above, was used as template for PCR reactions using primers 5'-GGGTAATTCTTATTTGTCGC-3' and 5'-TTAGCGTTGCCAGTGCTC B-3' for the *bla<sub>SHV</sub>* genes. Reaction conditions were: one cycle of 95°C/3 min; 30 cycles of 95°C/30 sec,

55°C/30 sec, 72°C/30 sec; and one cycle of 72°C/7 min.<sup>27</sup> PCR products were resolved by electrophoresis in 1% agarose gels. Amplicons were extracted from gels using the QIAquick Gel Extraction Kit (Qiagen) and sequenced with an automatic ABI Prism 310 DNA sequencer (Applied Biosystems). Sequence analysis was performed using Clone Manager Suite7, DNAMAN and Clustal W programs.

## RESULTS

*Resistance prevalence.* Resistance of all isolates to different antibiotics is listed in Table 1. Resistance to CAZ was found in 51/94 *K. pneumoniae* isolates, and in 5/7 *S. marcescens* isolates.

*ESBL-production phenotype.* All 48 CAZ-resistant isolates tested positive for ESBL production, using the double-disk test, and none for AmpC  $\beta$ -lactamase.

*PFGE genotyping.* While all 43 CAZ-resistant *K. pneumoniae* isolates had a distinct PFGE pattern, all 7 CAZ-resistant *S. marcescens* had an identical pattern, suggesting an outbreak (not shown).

*Plasmids.* CAZ-resistant *K. pneumoniae* isolates carried one to eight plasmids, whereas *S. marcescens* isolates had two to five. None of the isolates had the same plasmid profile, but all of *K. pneumoniae* share a plasmid of approximately 48 kb.

*Conjugal transfer.* CAZ-resistant *K. pneumoniae* isolates successfully transferred the ~48-kb plasmid to a recipient *E. coli* J53-2, along with the CAZ-resistance phenotype. Experiments using *S. marcescens* isolates did not yield CAZ-resistant transconjugants.

*Isoelectric focusing.* CAZ-resistant *K. pneumoniae* and *S. marcescens* isolates, and *E. coli* transconjugants, had two enzymes, with pI of

**Table 1.** Profile of susceptibility of nosocomial isolates of *K. pneumoniae* y *S. marcescens*

Antibiotic	<i>S. marcescens</i> , n = 7 % susceptibility	Antibiotic	<i>S. marcescens</i> , n = 7 % susceptibility	Antibiotic	<i>K. pneumoniae</i> , n = 94 % susceptibility	Antibiotic	<i>K. pneumoniae</i> , n = 94 % susceptibility
AMP	0% (0/7)	GEN	43% (3/7)	AMP	4.3% (4/94)	GEN	60.6% (57/94)
AMK	0% (0/7)	IMP	100% (7/7)	AMK	53.1% (50/94)	IMP	96.8% (91/94)
ATM	29% (2/7)	LVX	100% (7/7)	ATM	52.1% (49/94)	LVX	97.9% (92/94)
CAZ	29% (2/7)	TOB	29% (2/7)	CAZ	54.2% (51/94)	TOB	94.7% (88/94)
CIP	100% (7/7)	OFX	100% (7/7)	CIP	95.7% (90/94)	OFX	93.6% (88/94)
CTX	29% (2/7)	STR	29% (2/7)	CTX	55.3% (52/94)	STR	40.4% (38/94)
CXM	0% (0/7)	SXT	29% (2/7)	CXM	46.8% (44/94)	SXN	52.0% (49/94)
FEP	100% (7/7)	TET	29% (2/7)	FEP	94.7% (89/94)	TET	51.0% (48/94)
FOX	100% (7/7)	TIM	0% (0/7)	FOX	93.6% (88/94)	TIM	50.0% (47/94)
GAT	100% (7/7)	TZP	0% (0/7)	GAT	87.2% (82/94)	TZP	63.0% (59/94)

Disk diffusion method, following Clinical Laboratory Standard Institute (CLSI) guidelines.<sup>13</sup> 20 antibiotics were tested: Ampicillin (AMP), Amikacin (AMK), Aztreonam (ATM), Cefazidime (CAZ), Ciprofloxacin (CIP), Cefotaxime (CTX), Cefuroxime (CXM), Cefepime (FEP), Cefoxitin (FOX), Gatifloxacin (GAT), Gentamicin (GEN), Imipenem (IPM), Levofloxacin (LVX), Tobramycin (TOB), Ofloxacin (OFX), Streptomycin (STR), Trimethoprim-sulfametoxazole (SXT), Tetracycline (TET), Ticarcillin (TIM), Piperacillin (TZP).

5.4 and 8.2. The CAZ-hydrolyzing activity was detected in the pl 8.2 enzyme in all strains tested. This pl corresponds to the SHV family.<sup>28,29</sup>

*bla*<sub>SHV</sub> detection by PCR and sequencing. The amplification products using primers for *bla*<sub>SHV</sub> genes, in CAZ-resistant clinical isolates and trans-conjugants, showed the expected 900 bp size. Selected amplicons were sequenced; sequence alignments with gene *bla*<sub>SHV-1</sub> (access number AF148850.127<sup>30</sup>) and *bla*<sub>SHV-5</sub> (access number X55640.1.28.<sup>31</sup>) A 100% homology with SHV-5 type ESBL was found in all analyzed sequences.

## DISCUSSION

The prevalence of ESBL-producing *K. pneumoniae* varies widely: 7.5% in North America, 13.3% in Europe, 22.4% in the Asia-Pacific region, 44% in Latin America, 48.5% in Turkey, 51% in China and 72% in India.<sup>1,4</sup> ESBL-producing *K. pneumoniae* isolates reported here amount to 46%. The prevalence of ESBL-producing organisms is supposed to be related to the inappropriate use of antibiotics, and to the policies on antibiotic

usage in each region;<sup>32</sup> In México, antibiotics are among the most consumed drugs leading the Latin American region in antibiotic usage up to year 2005.<sup>33</sup>

The similarity in PFGE profiles among all CAZ-resistant *S. marcescens* isolates, strongly suggests an outbreak in the oncology ward; this kind of outbreaks are often caused by cross-contamination by medical staff,<sup>4</sup> and have a mortality rate of 10-20%.<sup>2,4,34</sup> Although the number of isolates reported here is small, two of these seven isolates were related to fatal outcomes, hence a 29% mortality rate. On the other hand, CAZ-resistant *K. pneumoniae* isolates all had distinct PFGE profiles, but they all carry a similar-size, conjugative plasmid bearing the *bla*<sub>SHV-5</sub> gene, suggesting that the plasmid has been transferred between different *K. pneumoniae* strains within the hospital in a manner consistent with the notion of epidemic plasmids, outlined nearly 30 years ago.<sup>35</sup> Such mobile elements can easily spread antibiotic resistance genes among a variety of bacterial species and across wide geographical areas. As the same *bla*<sub>SHV-5</sub> gene was found in all CAZ-resistant

*S. marcescens* isolates, it is even possible that the conjugative plasmid mentioned above was also transferred to a *S. marcescens* strain within the hospital, starting then an outbreak. Should this be the case, stringent monitoring of the emergence of resistance plasmids in *K. pneumoniae* in hospital environments could prevent the occurrence of outbreaks caused not only by that bacterial species, but also by other enteric bacteria acting as conjugal recipients. In order to optimize the use of molecular epidemiological monitoring in hospitals from low-income countries, it is important to assess which bacterial species are more likely to act as resistance and transfer "hot spots", so that early detection of dangerous phenotypes could prevent hospital-wide colonization and outbreaks.

## CONCLUSION

We found SHV-5 ESBL to be the most common underlying cause of third-generation cephalosporin resistance among *K. pneumoniae* and *S. marcescens* isolates causing sepsis in hospitalized children at our institution. The SHV-5 ESBL gene appears to reside in a highly mobile plasmid, capable of spreading among different *K. pneumoniae* clones and perhaps even to *S. marcescens*. We suggest designing control programs antibiotics limit the spread of multidrug-resistant bacteria and the spread of conjugative plasmids among strains.

## REFERENCES

1. Anthony M, Bedford A, Cooper T, Fry C, Health P, Kennea N, McCartney M, Patel B, Pollard T, Sharland M, Wilson P Managing and preventing outbreaks of Gram-negative infections in UK neonatal units. *Arch Dis Child Fetal Neonatal Ed* 2013;98:F549-F553.
2. Šiširak M, Hukić M An outbreak of multidrug-resistant *Serratia marcescens*: the importance of continuous monitoring of nosocomial infections. *Acta Med Acad* 2013;42:25-31.
3. Webster D, Young BC, Morton R, Collyer D, Batchelor B, Turton JF, Maharjan S, Livermore DM, Bejon P, Cookson BD, Boler IC Impact of a clonal outbreak of extended-spectrum  $\beta$ -lactamase-producing *Klebsiella pneumoniae* in the development and evolution of bloodstream infections by *K. pneumoniae* and *Escherichia coli*: an 11 year experience in Oxfordshire, UK. *J Antimicrob Chemother* 2011;66:2126-2135.
4. Dessi A, Puddu M, Testa M, Marcialis MA, Pintus MC, Fanos V *Serratia marcescens* infections and outbreaks in neonatal intensive care units. *J Chemother* 2009;21:493-499.
5. Bush K, Jacoby GA Updated functional classification of beta-lactamases. *Antimicrob Agents Chemother* 2010;54:969-976.
6. Bush K, Jacoby GA, Medeiros AA A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrob Agents Chemother* 1995;39:1211-1233.
7. Livermore DM Current epidemiology and growing resistance of gram-negative pathogens. *Korean J Intern Med* 2012;27:128-142.
8. Nordmann P Trends in beta-lactam resistance among Enterobacteriaceae. *Clin Infect Dis* 1998;27(Suppl 1):S100-S106.
9. Alcántar-Curiel D, Tinoco JC, Gayosso C, Carlos A, Daza C, Perez-Prado MC, Salcido L, Santos JI, Alpuche-Aranda CM. Nosocomial bacteremia and urinary tract infections caused by extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* with plasmids carrying both SHV-5 and TLA-1 genes. *Clin Infect Dis* 2004;38:1067-1074.
10. Garza-González E, Mendoza Ibarra SI, Llaca-Díaz JM, Gonzalez GM Molecular characterization and antimicrobial susceptibility of extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae isolates at a tertiary-care centre in Monterrey, Mexico. *J Med Microbiol* 2011;60:84-90.
11. Garza-Ramos U, Martínez-Romero E, Silva-Sánchez J SHV-type extended-spectrum beta-lactamase (ESBL) are encoded in related plasmids from enterobacteria clinical isolates from Mexico. *Salud Publica Mex* 2007;49:415-421.
12. Miranda G, Castro N, Leaños B, Valenzuela A, Garza-Ramos U, Rojas T, Solórzano F, Chihu L, Silva J Clonal and horizontal dissemination of *Klebsiella pneumoniae* expressing SHV-5 extended-spectrum beta-lactamase in a Mexican pediatric hospital. *J Clin Microbiol* 2004;42:30-35.
13. Morfín-Otero R, Mendoza-Olazarán S, Silva-Sánchez J, Rodríguez-Noriega E, Laca-Díaz J, Tinoco-Carrillo P, Petersen L, López P, Reyna-Flores F, Alcántar-Curiel D, Garza-Ramos U, Garza-González E Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum  $\beta$ -lactamase. *Microb Drug Resist* 2013;19:378-383.
14. Mosqueda-Gómez JL, Montañón-Loza A, Trolón AL, Cervantes C, Bobadilla-del-Valle JM, Silva-Sánchez J, Garza-Ramos U, Villasís-Keever A, Galindo-Fraga A, Palacios GM, Ponce-de-Leon A, Sifuentes-Osornio J. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae*. A case-control study. *Int J Infect Dis* 2008;12:653-659.

15. Muro S, Garza-González E, Camacho-Ortiz A, Gonzalez GM, Llaca-Díaz JM, Bosques F, Rositas F Risk factors associated with extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae nosocomial bloodstream infections in a tertiary care hospital: a clinical and molecular analysis. *Chemotherapy* 2012;58:217-224.
16. Silva J, Gatica R, Aguilar C, Becerra Z, Garza-Ramos U, Velázquez M, Miranda G, Leaños B, Solórzano F, Echániz G Outbreak of infection with extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in a Mexican hospital. *J Clin Microbiol* 2001;39:3193-3196.
17. Silva-Sánchez J, Garza-Ramos JU, Reyna-Flores F, Sánchez-Perez A, Rojas-Moreno T, Andrade-Almaraz V, Pastrana J, Castro-Romero JI, Vinuesa P, Barrios H, Cervantes C Extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae causing nosocomial infections in Mexico. A retrospective and multicenter study. *Arch Med Res* 2011;42:156-162.
18. Espinoza de los Monteros LE, Silva-Sánchez J, Jiménez LV, Rojas T, Garza-Ramos U, Valverde V Outbreak of infection by extended-spectrum beta-lactamase SHV-5-producing *Serratia marcescens* in a Mexican hospital. *J Chemother* 2008;20:586-592.
19. CLSI (2011) Performance standards for antimicrobial susceptibility testing. Wayne, PA: Clinical and Laboratory Standards Institute.
20. Pfaller MA, Segreti J Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. *Clin Infect Dis* 2006;42(Suppl 4):S153-S163.
21. Gouby A, Neuwirth C, Bourg G, Bouziges N, Carles-Nurit MJ, Despau E, Ramuz M Epidemiological study by pulsed-field gel electrophoresis of an outbreak of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in a geriatric hospital. *J Clin Microbiol* 1994;32:301-305.
22. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J Clin Microbiol* 1995;33:2233-2239.
23. Mathew A, Harris AM, Marshall MJ, Ross GW The use of analytical isoelectric focusing for detection and identification of beta-lactamases. *J Gen Microbiol* 1975;88:169-178.
24. Bush K, Singer SB Effective cooling allows sonication to be used for liberation of beta-lactamases from gram negative bacteria. *J Antimicrob Chemother* 1989;24:82-84.
25. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory.
26. Miller JH (1992) Experiments in molecular genetics. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
27. Siu LK, Lu PL, Hsueh PR, Lin FM, Chang SC, Luh KT, Ho M, Lee CY Bacteremia due to extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes. *J Clin Microbiol* 1999;37:4020-4027.
28. Babini GS, Livermore DM Are SHV beta-lactamases universal in *Klebsiella pneumoniae*? *Antimicrob Agents Chemother* 2000;44:2230.
29. Gutmann L, Ferré B, Goldstein FW, Rizk N, Pinto-Schuster E, Acar JF, Collatz E SHV-5, a novel SHV-type beta-lactamase that hydrolyzes broad-spectrum cephalosporins and monobactams. *Antimicrob Agents Chemother* 1989;33:951-956.
30. Bradford PA Automated thermal cycling is superior to traditional methods for nucleotide sequencing of bla(SHV) genes. *Antimicrob Agents Chemother* 1999;43:2960-2963.
31. Billot-Klein D, Gutmann L, Collatz E Nucleotide sequence of the SHV-5 beta-lactamase gene of a *Klebsiella pneumoniae* plasmid. *Antimicrob Agents Chemother* 1990;34:2439-2441.
32. Coque TM, Baquero F, Canton R Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. *Euro Surveill* 2008;13:pii19044.
33. Wirtz VJ, Dreser A, Gonzales R Trends in antibiotic utilization in eight Latin American countries, 1997-2007. *Rev Panam Salud Publica* 2010;27:219-225.
34. Iosifidis E, Farmaki E, Nedelkopoulou N, Tsivitanidou M, Kaperoni M, Pentsoglou V, Pournaras S, Athanasiou-Metaxa M, Roilides E Outbreak of bloodstream infections because of *Serratia marcescens* in a pediatric department. *Am J Infect Control* 2012;40:11-15.
35. O'Brien TF, Pla MP, Mayer KH, Kishi H, Gilleece E, Syvanen M, Hopkins JD Intercontinental spread of a new antibiotic resistance gene on an epidemic plasmid. *Science* 1985;230:87-88.